Magazine
Operon Biotech refers to themselves as the “Composite Coagulation Experts”, and rightfully so. Here’s why – their affable team with 50+ years of combined experience, strong product line, excellent market standing, proven technical knowledge and the dynamic network of distributors are second to none.
They have an irrefutable presence in the state of Karnataka - in both POCT and lab diagnostics - and a significant nationwide presence for POCT devices. Operon Biotech also has distinguished clients like Manipal Hospital Group, NH Group, NU Group, Top notch Medical College Hospitals and Leading Government Hospitals to name a few, to their credit. With the combined range of instrumentation, reagents and consumables and POCT, it is safe to say that they are a force to reckon with.
Tapping on Market Opportunities
The current market of biomedical services and IVD industry is evolving by leaps and bounds in India, and Operon Biotech is fast becoming a key player. “The global IVD market is about Rs 6.52 L Cr., while the Indian IVD industry is about Rs 67,500 Cr. with a CAGR at 10.2 percent. Outlining the factors driving this growth, Afser Shariff explained, “Rapid adaptation of the IVD industry to the rising demand for high volume testing, the pandemic, increased health awareness, geriatric
population, disposable incomes, insurance coverage, government thrust and impetus has played a big role. The availability of efficient and accurate automated systems with error-free diagnosis is another factor”, Afser added.
Elaborating on the company’s positioning, Afser said, “While the global markets for coagulation stands at Rs 37,000 Cr., in India, they are about Rs 1,000 Cr., growing at a CAGR of 10.2 percent PA. Operon Biotech is targeting at least 100 Cr. from these markets both domestically and globally by the year 2030.,” In India they are focused on tier-2 and tier-3 cities, while in the global markets they are focused on developing countries.
Growing Product Portfolio
Operon Biotech’s impressive product portfolio comprises a series of instruments under both lab diagnostics as well as POCT under coagulation. Be it a simple single channel system for a clinical Lab or an self-testing device for INR monitoring to an affordable entry level automation to mid-sized automation - they have it all. They recently added ACT machine and TEG, products from SONOCLOT, USA, in their coagulation portfolio.
What sets them apart from competitors is their ability to understand the customer’s pain points and give them practical solutions. Coagulation business for this company is a core offering and not just an add up product, like in case of most competitors.
With a passion to grow and leadership that’s inventive, Operon Biotech has already charted their path to scale greater heights.
“Under reagents we offer small packs of two ML to large packs of 10 ML keeping in mind the various segments of customers. All our reagents are backed with excellent quality controls”, says After, before adding, “We offer our customers a full range in coagulation testing be it routine PT/APTT/FIB and TT, to specialty testing like Factor Assay Testing, Thrombotic Panel Testing, Inhibitor Testing and Fibrinolytic Testing. We also offer D-Dimer testing on various platforms on Lab automation, Chemistry, Immunoassay, Latex and Rapid testing”. Operon Biotech’s non-core products comprises Haematology three part analyser by the name Triscan, CLIA systems from Maglumi, Glucometer and HB metre under POCT and semi automated chemistry ChemXpress + an 200T through put biochemistry analyser.
.jpg "Precise Fasteners: Committed To Fulfilling Client Expectations, Every Time!")
